Fernández-Cruz Eduardo, Navarro Joaquín, Rodríguez-Sainz Carmen, Gil Juana, Moreno Santiago, González-Lahoz Juan, Carbone Javier
University General Hospital Gregorio Marañón, Immunology Department, Complutense University of Madrid, Madrid, Spain.
Expert Rev Vaccines. 2003 Dec;2(6):739-52. doi: 10.1586/14760584.2.6.739.
Immune-based therapies, such as therapeutic vaccination, that might preserve, restore, enhance and induce new HIV-specific immunologic responses are currently being explored. HIV-specific immunotherapy with Remune (The Immune Response Corp.) offers the opportunity to boost immune responses against HIV-1. The clinical trial program in a wide range of subjects has established the efficacy of Remune in stimulating an appropriate immune response in HIV-positive individuals. Furthermore, a recent unblinded study conducted in Europe has documented a significant effect of Remune on viral load. Evidence regarding clinical end points is more difficult to collect. The same studies have revealed no serious safety issues in a total of more than 2000 Remune-treated patients. It is therefore reasonable to suggest that the risk-benefit ratio of Remune could be positive.
目前正在探索基于免疫的疗法，如治疗性疫苗接种，这类疗法可能会保留、恢复、增强并诱导新的HIV特异性免疫反应。使用Remune（免疫反应公司）进行的HIV特异性免疫疗法为增强针对HIV-1的免疫反应提供了机会。针对广泛受试者的临床试验项目已证实Remune在刺激HIV阳性个体产生适当免疫反应方面的疗效。此外，最近在欧洲进行的一项非盲法研究记录了Remune对病毒载量的显著影响。关于临床终点的证据更难收集。同样的研究表明，在总共2000多名接受Remune治疗的患者中没有发现严重的安全问题。因此，有理由认为Remune的风险效益比可能是有利的。
